Upsher-Smith Laboratories, LLC, a United States-based pharmaceutical company, announced on Monday that it has launched its Fluphenazine Hydrochloride Tablets, USP in 1mg, 2.5mg, 5mg, and 10mg strengths.
According to IQVIA, the product market had US sales of around USD30m for the 12 months ending January 2023.
The product is a generic version of the brand product, Prolixin. Prolixin is a registered trademark of E.R. Squibb & Sons, Inc.
ScinoPharm Taiwan secures first US FDA approval for complex multiple sclerosis generic
ScinoPharm Taiwan's Glatiramer Acetate Injection approved by US FDA
International Isotopes Inc to change name to Radnostix Inc
Galmed Pharmaceuticals reports topline results for combination of Aramchol, Stivarga and metformin
Ingenus Pharmaceuticals' generic equivalent to Premarin receives US FDA approval
EirGenix signs second global exclusive licensing deal with Sandoz
Padagis invests USD36m to expand manufacturing in Minneapolis
Newbury Pharmaceuticals gains Danish approval for generic ivermectin cream